Key Insights

Highlights

Success Rate

92% trial completion (above average)

Published Results

206 trials with published results (24%)

Research Maturity

505 completed trials (58% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

4.8%

42 terminated out of 869 trials

Success Rate

92.3%

+5.8% vs benchmark

Late-Stage Pipeline

26%

226 trials in Phase 3/4

Results Transparency

41%

206 of 505 completed with results

Key Signals

206 with results92% success42 terminated

Data Visualizations

Phase Distribution

677Total
Not Applicable (308)
Early P 1 (4)
P 1 (57)
P 2 (82)
P 3 (130)
P 4 (96)

Trial Status

Completed505
Recruiting101
Unknown97
Terminated42
Not Yet Recruiting40
Active Not Recruiting32

Trial Success Rate

92.3%

Benchmark: 86.5%

Based on 505 completed trials

Clinical Trials (869)

Showing 20 of 20 trials
NCT05164172Phase 3RecruitingPrimary

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

NCT07645924Phase 3Not Yet RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

NCT06323928Phase 2CompletedPrimary

A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

NCT05987592Not ApplicableRecruitingPrimary

BE WELL With Migraine: Brain Education and WELLness With Migraine

NCT06409832RecruitingPrimary

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment

NCT05861427Phase 3CompletedPrimary

Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine

NCT06409845CompletedPrimary

Effectiveness and Tolerability of Eptinezumab

NCT07642414Not ApplicableRecruitingPrimary

A Comprehensive Digital Care Program for Migraine Management

NCT07594769Phase 1RecruitingPrimary

A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults

NCT06616194Phase 3RecruitingPrimary

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

NCT04100135Not ApplicableTerminatedPrimary

GORE® CARDIOFORM Septal Occluder Migraine Clinical Study

NCT07634146Not ApplicableNot Yet RecruitingPrimary

Evaluation of the Migraceutics® Phase-Specific Dietary Supplement Regimen on Quality of Life, Work Productivity, and Biomarkers in Adult Migraineurs: The Migraceutics® START Study

NCT01016834Phase 4CompletedPrimary

Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine

NCT06170281Not ApplicableSuspendedPrimary

Sequential, Multiple Assignment, Double Randomized Preference, Migraine Behavioral Trial

NCT07633067Not ApplicableNot Yet RecruitingPrimary

Safety and Efficacy of Middle Meningeal Artery Embolization for the Treatment of Migraine.

NCT05415020Not ApplicableRecruitingPrimary

Determining the Utility of a Behavioral Intervention in Chronic Migraine

NCT00071786Completed

Family Study of Affective and Anxiety Spectrum Disorders

NCT05125302Phase 3RecruitingPrimary

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

NCT07457268Not ApplicableCompletedPrimary

Effect of Transcutaneous Auricular Trigeminal Nerve Stimulation on Migraine

NCT07125820Not ApplicableCompletedPrimary

A Dual Intervention in Migraine Treatment: Tens and Exercise

Scroll to load more

Research Network

Activity Timeline